Shanghai Henlius Biotech, Inc. Board announced that Mr. Zihou Yan (Mr. Yan) has tendered his resignation from a non-executive director of the Company, a member of the Strategy Committee and a member of the Environmental, Social and Governance Committee with effect from 17 July 2023 due to his retirement. Mr. Yan has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the Shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | +5.49% | +35.54% |
24/05 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
24/05 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
-1.64% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee